论文部分内容阅读
胸膜腔内BCG免疫治疗是至今已报导的唯一一种配合手术的、有希望的全身性抗肿瘤辅助措施。初步的试验说明这种技术只对Ⅰ期病变有效。以往经验说明用BCG产生肿瘤免疫性的最有效方法是瘤内直接注射。而要在一个具有原发性肿瘤、区域淋巴结转移和播散性微小血管转移的宿主身上产生全身性抗肿瘤免疫性的最有效方法是在用BCG作瘤内注射后4～6周完全切除肿瘤和区域淋巴结。本文试图评价在肺切除前作BCG病灶内直接注射的施行可能性和毒性。病例和方法用0.5或1毫升Glaxo BCG对25例肺癌患者作瘤内BCG注射,注射前多数患者均作中浓度PPD的
Pleural immunotherapy of pleural cavity is the only one that has been reported so far and is a promising systemic anti-tumor aid. Preliminary tests indicate that this technique is only effective for stage I lesions. Past experience has shown that the most effective method for generating tumor immunity using BCG is direct intratumoral injection. The most effective way to generate systemic anti-tumor immunity in a host with primary tumors, regional lymph node metastases, and disseminated microvascular metastases is to completely remove the tumor 4 to 6 weeks after intratumoral injection of BCG. And regional lymph nodes. This article attempts to evaluate the feasibility and toxicity of direct injection of BCG lesions before pulmonary resection. Cases and Methods Intratumoral BCG injection was performed on 25 patients with lung cancer using 0.5 or 1 ml of Glaxo BCG. Most patients had moderate PPD before injection.